Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy

Current liver‐directed gene therapies look for adeno‐associated virus (AAV) vectors with improved efficacy. With this background, capsid engineering is explored. Whereas shuffled capsid library screenings have resulted in potent liver targeting variants with one first vector in human clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Meumann, Nadja, Cabanes‐Creus, Marti, Ertelt, Moritz, Navarro, Renina Gale, Lucifora, Julie, Yuan, Qinggong, Nien‐Huber, Karin, Abdelrahman, Ahmed, Vu, Xuan‐Khang, Zhang, Liang, Franke, Ann‐Christin, Schmithals, Christian, Piiper, Albrecht, Vogt, Annabelle, Gonzalez‐Carmona, Maria, Frueh, Jochen T., Ullrich, Evelyn, Meuleman, Philip, Talbot, Steven R., Odenthal, Margarete, Ott, Michael, Seifried, Erhard, Schoeder, Clara T., Schwäble, Joachim, Lisowski, Leszek, Büning, Hildegard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles: Liver Pathobiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936986/
https://www.ncbi.nlm.nih.gov/pubmed/35976053
http://dx.doi.org/10.1002/hep.32733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936986/
https://www.ncbi.nlm.nih.gov/pubmed/35976053
http://dx.doi.org/10.1002/hep.32733

Ejemplares similares